Danaher’s Leica to buy Statlab to expand pathology footprint
· shani alexander
AI Briefing
- • Danaher's Leica Biosystems to acquire Statlab Medical Products for expansion in pathology.
- • Acquisition aims to strengthen diagnostics and anatomical pathology portfolio with consumables and instruments.
- • Deal valuation estimated to be over $1 billion, according to RBC Capital Markets analyst.
Source Summary
Leica Biosystems GmbH, agreed to buy Statlab Medical Products in a move that will strengthen parent company Danaher Corp.'s diagnostics and anatomical pathology portfolio with a broader range of consumables and instruments. Although the financial terms were not disclosed, RBC Capital Markets analyst Dan Leonard reckoned that the deal could be valued at more than $1 billion.
Advertisement